Introduction
============

Diabetic retinopathy is a major complication in patients with diabetes and it can lead to severe visual decrease in a high percentage of diabetic patients ([@b69]; [@b71]). Although the precise mechanism(s) for the onset and progression of diabetic retinopathy has still not been determined, recent studies have indicated that neuronal and vascular abnormalities are associated with the pathogenesis of early diabetic retinopathy ([@b10]; [@b95]; [@b5]; [@b63]; [@b70]). The neuronal abnormalities in the early stage of diabetic retinopathy are difficult to observe and evaluate by routine clinical tests, but ophthalmologists should consider neuronal abnormalities, including the death of retinal ganglion cell (RGCs), when evaluating eyes with diabetic retinopathy. This is important because the death of retinal neurons is irreversible and directly affects the visual function ([@b69]; [@b71]).

The endoplasmic reticulum (ER) is a critical intracellular organelle, which has several vital functions such as protein synthesis ([@b13]), protein transport ([@b76]), and acts as a reservoir of Ca^2+^ ([@b67]). The accumulation of unfolded proteins or an upset in the Ca^2+^ homeostasis in the ER will activate the ER stress response, eg, the unfolded protein response (UPR) and the ER overload response ([@b83]; [@b58]). Most importantly, ER stress activates several cell death pathways including the caspase-12-dependent pathway ([@b66]), apoptosis signal-regulating kinase 1 (ASK1) -- c-Jun N-terminal kinase (JNK) pathway ([@b68]) and the PKR-like endoplasmic reticulum kinase (PERK) -- C/ERB homologous protein (CHOP) pathway ([@b60]) ([Figure 1](#fig1){ref-type="fig"}).

![Hypothesized scheme of the ER stress-mediated cell death pathways. At least, three major cell death pathways are associated with ER stress-induced cell death.\
**Abbreviations:** ER, endoplasmic reticulum; TRAF2, tumor necrosis factor receptor-associated factor 2; ASK1, apoptosis signal-regulating kinase 1; SEK1, SAPK/ERK kinase 1; MKK7, mitogen-activated protein kinase kinase 7; JNK, c-Jun N-terminal kinase; ATF4, activating transcription factor 4; PERK, PKR-like endoplasmic reticulum kinase; elF2α, a subunit of translation eukaryotic initiation factor 2; CHOP, C/ERB homologous protein.](vhrm0401-115-01){#fig1}

The results of recent studies have shown that ER stress-mediated cell death is associated with the death of pancreatic β-cells in patients with diabetes ([@b73], [@b72]; [@b55]). In addition, a recent study reported that the ER stress-induced apoptosis is related to changes in the glucose concentration and results in the death of pericytes ([@b41]). [@b85] suggested that the ER stress-mediated activating transcriptional factor 4 (ATF4) activation was associated with an over-expression of vascular endothelial growth factor (VEGF). In addition, recent studies indicate that ER stress-induced apoptosis is involved in the death of neurons in the brain and retina under different physiological conditions ([@b35]; [@b98]; [@b42]; [@b54]; [@b96]; [@b105]; [@b40]; [@b8]; [@b88]).

One therapeutic strategy that might be used to prevent the development and progression of type 2 diabetes is the inhibition of ER stress. This would then block the ER stress-induced pancreatic β-cell death, and may also prevent the onset and progression of diabetic retinopathy. We shall discuss the possible role of ER stress in the pathogenesis of diabetic retinopathy and describe potential therapeutic strategies to block the development and the progression of diabetic retinopathy.

ER stress-mediated pancreatic β-cell death in diabetes
======================================================

The ER is involved in the maintenance of cellular homeostasis by inducing the UPR. The UPR of mammals is mediated by at least three types of ER transmembrane proteins; IRE1 (protein kinase and site-specific endoribonuclease) ([@b97]; [@b102]), PERK ([@b37]), and ATF6 ([@b107]). Under diabetic conditions, the pancreatic β-cells are continuously exposed to oxidative stress, eg, exposure to reactive oxygen species (ROS; [@b48]) and to nitrous oxide (NO; [@b73]). The ER is highly developed in pancreatic β-cells because of the continuous insulin secretion. Thus, it seems that even under physiological conditions, a potential ER stress is present because there are many unfolded proteins and premature proteins in the ER of pancreatic β-cells ([@b38]; [@b103]). These unfolded and premature proteins can easily become targets of ROS and NO ([@b73]; [@b48]). Once the ER stress is increased in pancreatic β-cells, the JNK- and CHOP-mediated cell death pathways are activated ([@b73], [@b72]; [@b48]). The activation of the JNK pathway under diabetic stress is known to induce the serine phosphorylation of insulin receptor substance 1, which in turn leads to insulin resistance ([@b74]). When the number of pancreatic β-cell is decreased, ER stress is increased in the remaining pancreatic β-cells to compensate for the reduced insulin secretion leading to pancreatic β-cell dysfunction ([@b103]; [@b81]). Thus, ER stress-mediated pancreatic β-cell death is critical and a key alteration for the pathogenesis of type 2 diabetes.

ER stress involved in vascular abnormalities in eyes with diabetic retinopathy
==============================================================================

The loss of pericytes from the microvessels in diabetic retinas is one of the characteristic pathological changes in the early stage of diabetic retinopathy. The results of a recent study indicated that the UPR, activated by ER stress, is induced in retinal pericytes by the changes in the glucose concentration ([@b41]). Thus, ER stress-mediated cell death is the common pathology in the death of pancreatic β-cells and pericytes in diabetes.

VEGF plays important roles in the pathogenesis of diabetic retinopathy ([@b90]; [@b3]; [@b59]; [@b43]; [@b82]; [@b32]). The expression of VEGF is increased in diabetic retinas by the high-glucose, ischemia, and hypoxia, and this leads to the development of neovascularization and/or increased vascular permeability ([@b90]; [@b3]; [@b59]; [@b43]; [@b82]; [@b32]). Abcouwer et al showed that the glutamine deprivation-induced ER stress is associated with an up-regulation of VEGF expression in human retinal pigment epithelial cells ([@b1]). [@b85] suggested that the homocysteine-induced ER stress is related to the over-expression of VEGF under the control of ATF4. Hyperglycemia has been suggested to increase the intracellular homocysteine levels in the retinal pigment epithelium cells. Thus, there is good evidence that the diabetic stress-induced ER stress is involved in vascular abnormalities such as pericyte loss and neovascularization.

ER-stress-mediated neuronal cell death
======================================

Recent studies have shown that RGCs die at the early stage of diabetes ([@b10]; [@b5]; [@b70]). The neuronal abnormalities, such as RGC death, are irreversible and may precede the vascular abnormalities including the increased vascular permeability in diabetic retinas. This is observed even in retinas with a clinical diagnosis of non-diabetic retinopathy, however neuronal abnormalities, such as the reduction of retinal nerve fiber thickness, can be detected by optical coherence tomography even at this stage ([@b94]).

[@b35] suggest that an upset of the Ca^2+^ homeostasis in the ER caused by mutations in presenilin-1 is associated with the neuronal cell death in Alzheimer's disease. Recently, many studies have reported that the ER stress-mediated neuronal cell death is related to the pathogenesis of various neuronal diseases in the brain and retina, eg, polyglutamine diseases ([@b68]), Parkinson's disease ([@b42]), amyotrophic lateral sclerosis ([@b98]; [@b105]), acute brain disorders ([@b54]; [@b96]; [@b40]), and retinal ischemia ([@b8]; [@b88]).

Other studies have shown that the PERK-CHOP pathway, one of the ER stress-mediated pathways that is induced in ischemic retinas, is related to neuronal cell death ([@b8]; [@b88]). It is well-known that under ischemic stress, an increase of intracellular Ca^2+^ level disturbs the ER Ca^2+^ homeostasis which in turn leads to ER stress-induced neuronal degeneration ([@b101]). Unfolded proteins that accumulate in the ER in ischemic retinas become targets of ROS and NO. Thus, it seems reasonable that in ischemic retinas, the ER stress-mediated cell death pathways are related to the neuronal degeneration.

We have examined the IRE1-JNK pathway to determine if it is associated with the neuronal death in ischemic retinas using the ischemia-reperfusion injury model (unpublished data). Our results suggested that the expressions of IRE1α and tumor necrosis factor receptor-associated factor 2 (TRAF2) were significantly increased in the ischemic retinas compared to that in control retinas. In addition, we found that the expression of ASK1, SAPK/ERK kinase 1 (SEK1), and JNK were expressed in the same degenerating neurons of ischemic retinas (unpublished data). Thus, not only the PERK-CHOP pathway but also the IRE1-JNK pathway is associated with neuronal death in ischemic retinas.

The exact mechanism leading to the death of RGCs has not been conclusively determined especially at the early stage of diabetic retinopathy. One possible link between vascular abnormalities and neuronal abnormalities may be the changes in the glial cells at the early stage of diabetic retinopathy ([Figure 2](#fig2){ref-type="fig"}). Glial processes make contact with both the blood vessels and neurons, and form the blood-retinal barrier ([@b50]) ([Figure 2](#fig2){ref-type="fig"}). Glial cells can maintain the blood-retinal barrier by expressing VEGF, and there are many studies that have shown interactions between glial cells and neuronal cells in the retina ([@b33]; [@b84]; [@b36]). During the onset and the progression of diabetic retinopathy, Müller cells are changed, eg, up-regulation of glial fibrillary acidic protein (GFAP) and accumulation of gamma-aminobutyric acid ([@b44]; [@b57]; [@b9]; [@b86]). [@b77] suggested that glial abnormalities, eg, swelling of the cell body, may lead to the retinal edema detected in diabetic retinas. Thus, neuro-glial interactions may be involved at the onset and the progression of diabetic retinopathy, and glial changes may be related to both neuronal and vascular abnormalities at the early stage of diabetic retinopathy ([Figure 2](#fig2){ref-type="fig"}).

![Hypothesized scheme of the pathogenesis of early diabetic retinopathy. The characteristic changes of early diabetic retinas may be glial changes, which in turn leads to vascular and neuronal abnormalities such as increased vascular permeability or neuronal cell death. The ideal therapies for diabetic retinopathy may be the improvement of both vascular and neuronal abnormalities.\
**Abbreviations:** GFAP, glial fibrillary acidic protein; GABA, gamma-aminobutyric acid.](vhrm0401-115-02){#fig2}

The glutamate levels are known to be elevated in the vitreous of diabetic patients ([@b2]), which could lead to neuronal cell death. Because an over-stimulation of neurons by glutamate upsets the Ca^2+^ homeostasis in the ER, ER stress may be present in degenerating neurons under diabetic stress.

Because there is very little evidence of a direct association of ER stress and the pathogenesis of diabetic retinopathy, ER stress may be an epiphenomenon and/or only one of the players, perhaps with a minor role, in the development of diabetic retinopathy. Thus, although ER-stress-related factors may be promising targets for the prevention and the progression of diabetic retinopathy, additional studies are needed to determine the relationship between ER stress and neuronal cell death in diabetic retinas.

Potential therapeutic strategies for diabetic retinopathy
=========================================================

An epidemiological study performed by the Japanese Ministry of Welfare in 2005 showed that diabetic retinopathy was the second most common eye disease to cause blindness in the Japanese. Over 3,000 patients with diabetic retinopathy lose their vision each year in Japan. This indicates that the current management and therapies for diabetic retinopathy are not sufficient to prevent the progression to blindness in patients with diabetic retinopathy. To reduce the number of patients who lose their vision from diabetic retinopathy, new therapeutic strategies must be established to prevent the onset and the progression of the diabetic retinopathy.

At present, the standard treatments for diabetic retinopathy include: control of the blood glucose levels and the blood pressure ([@b52]; [@b17], [@b18]; [@b99]; [@b19]; [@b106]; [@b64]), focal laser photocoagulation ([@b28], [@b29], [@b30]), pan-retinal laser photocoagulation ([@b20], [@b21]), and early vitrectomy ([@b22], [@b23], [@b23], [@b24], [@b25]). Although the diabetic retinopathy continues to progress in some patients in spite of good control of blood glucose and blood pressure, a tight control of blood glucose levels and blood pressure is the first choice for the treatment of diabetic retinopathy.

Focal laser treatment significantly decreased the risk of visual disturbances in diabetic patients with macular edema. However, side effects, eg, foveal burns, central visual field defects and retinal fibrosis, are not uncommon. Pan-retinal photocoagulation also has many side effects such as visual field constriction, night blindness, and exacerbation of macular edema. However, pan-retinal laser photocoagulation significantly decreased the risk of visual disturbances in diabetic patients with severe non-proliferative and proliferative retinopathy. Early vitrectomy reduced the risk of visual disturbances in diabetic patients with proliferative retinopathy and vitreous hemorrhage. Again, there are many side effects of vitrectomy including vitreous hemorrhage, retinal detachment, neovascular glaucoma, and infection.

Intravitreal or sub-Tenon injections of triamcinolone acetonide (TA) has been recently used to treat the macular edema common in diabetic patients, and during the early post-TA period, there were improvements in both the macular edema and visual acuity ([@b62]; [@b7]; [@b91]; [@b46]). Steroids are known to up-regulate the expression of tight junctions proteins, eg, occludin and ZO-1, in endothelial cells, and this increase reduce the increased vascular permeability in the retina ([@b4]). Unfortunately, repeated injections of TA are frequently required, and there are many side effects such as increased intraocular pressure, cataracts, and infections ([@b34]; [@b45], [@b46]; [@b104]). Although long-term follow-up studies of TA must be made, the treatments by TA may be considered together with laser treatments and vitrectomy in diabetic patients with severe macular edema.

There are many medical therapies that are being tried to prevent the development and progression of diabetic retinopathy, eg, aspirin ([@b31]; [@b14]), anti-VEGF agents ([@b16]; [@b6]; [@b15]; [@b93]), protein kinase C inhibitors ([@b79], [@b80]; [@b78]), growth hormone inhibitors ([@b51]), and aldose reductase inhibitors ([@b92]). However, [@b65] stated that these treatments cannot be recommended for routine use because evidence to support their use has not been published.

The most important factor to consider in the management and the treatment of diabetic retinopathy is the protection of visual function. Because the onset and progression of neuronal and vascular abnomralities lead to visual dysfunction, the targets of the therapeutic methods should be the factors that are common to both vascular and neuronal abnormalities of diabetic retinopathy. Thus, we have stated in an earlier review article that two of the candidates common to both vascular and neuronal abnormalities in diabetic retinopathy are tumor necrosis factor-alpha and Bax ([@b69]). ER stress-related factors should also be considered as targets of new therapeutic strategies for diabetic retinopathy as well as the targets of new therapies for type 2 diabetes because ER stress is also related to pancreatic β-cell death and insulin resistance in patients with type 2 diabetes.

The results of a recent study showed that oral administration of chemical chaperones, 4-phenyl butyric acid or taurine-conjugated ursodeoxycholic acid, alleviated ER stress and improved the action of systemic insulin in diabetic animals ([@b75]). Although the precise mechanism involved in the improvement of type 2 diabetes is unclear, these chemical chaperones may stabilize protein conformation and improve the folding capacity of the ER, which in turn would reduce the ER stress in these diabetic animals. These chemical chaperones may become a standard treatment for type 2 diabetes because of their safety profiles in vivo ([@b61]; [@b49]).

Recently, a Bax inhibitor-1 (BI-1) was identified to be an anti-apoptotic protein in mammals ([@b11]), and this is relevant because BI-1 can regulate a cell death pathway involved in ER stress ([@b12]). In addition, an over-expression of BI-1 can protect against the neuronal cell death induced by ER stress ([@b27]). Although the mechanism for this protective effect was not determined, a recent study showed that BI-1 can inhibit ER stress proteins such as CHOP, IRE1α or phospho-JNK ([@b56]). The activity of BI-1 may provide clues on developing new ways to regulate the ER stress-induced apoptosis. For example, brain-derived neurotrophic factor (BDNF), which is known to reduce the neuronal degeneration of diabetic retinas in vivo ([@b87]), prevents ER stress-mediated neuronal cell death by suppressing caspase-12 activation in vitro ([@b89]).

Although these neuroprotective therapies may be promising, the prevention of neuronal cell death under chronic diabetic stress may have limitations. Even if one major cell death pathway is blocked, another cell death pathway may become activated. Even when apoptosis can be blocked, other types of cell death such as necrosis or autophagy may be induced ([@b53]; [@b39]; [@b100]). Thus, even if we can establish neuroprotective therapies for diabetic retinopathy, the first choice of the treatment for diabetic retinopathy must still be the standard treatment of controlling blood glucose levels and blood pressure to reduce the causes of diabetic stress.

In conclusion, ER stress is involved in the pathogenesis of type 2 diabetes and diabetic retinopathy. The reduction of ER stress by chemical chaperones such as 4-phenyl butyric acid or taurine-conjugated ursodeoxycholic acid may become one of the standard treatments for type 2 diabetes. Such treatments may be helpful in preventing the development of diabetic retinopathy. Additional studies are required to determine the optimal methods to reduce ER stress in patients with diabetic retinopathy.
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